Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Total Non-Current Liabilities (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Total Non-Current Liabilities for 4 consecutive years, with $48.7 million as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities rose 12.87% to $48.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $48.7 million through Dec 2025, up 12.87% year-over-year, with the annual reading at $48.7 million for FY2025, 12.87% up from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $48.7 million at Orchestra BioMed Holdings, down from $60.8 million in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $60.8 million in Q3 2025, with the low at $5.3 million in Q1 2022.
  • Average Total Non-Current Liabilities over 4 years is $39.2 million, with a median of $41.5 million recorded in 2022.
  • The sharpest move saw Total Non-Current Liabilities surged 586.77% in 2023, then rose 12.87% in 2025.
  • Over 4 years, Total Non-Current Liabilities stood at $40.9 million in 2022, then fell by 11.02% to $36.4 million in 2023, then rose by 18.5% to $43.2 million in 2024, then grew by 12.87% to $48.7 million in 2025.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $48.7 million, $60.8 million, and $42.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.